<DOC>
	<DOCNO>NCT02675465</DOCNO>
	<brief_summary>This study international , multi-center , study Pompe disease patient currently receive enzyme-replacement therapy ( ERT ) . The purpose study find co-administration investigational new drug ATB200 AT2221 safe adult Pompe disease .</brief_summary>
	<brief_title>First-In-Human Study Evaluate Safety , Tolerability , PK Intravenous ATB200 Alone When Co-Administered With Oral AT2221</brief_title>
	<detailed_description>This open-label , fixed-sequence , ascending-dose , first-in-human study evaluate effect highly target rhGAA ( ATB200 ) co-administered chaperone ( AT2221 ) . The study aim evaluate safety , tolerability , pharmacodynamics ( PD ) , immunogenicity ATB200 co-administered AT2221 . The study conduct 3 stage . In Stage 1 , safety , tolerability , PK evaluate follow sequential single ascending dose intravenously infused ATB200 . In Stage 2 , safety , tolerability , PK evaluate follow single- multiple-ascending dose combination ATB200 AT2221 . In Stage 3 , long term safety efficacy assess follow 24 month treatment ATB200 co-administered AT2221 ( Miglustat ) No Muscle biopsy perform study .</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<criteria>Key Male female subject 18 65 year age , inclusive Diagnosis Pompe disease Enzyme Replacement Therapy ( ERT ) experience subject ( ambulatory ) : Has receive ERT alglucosidase alfa previous 26 year , inclusive Subject currently receive alglucosidase alfa ( myozyme/lumizyme ) , frequency every week Must able walk 200500 meter 6Minute Walk Test ( 6MWT ) Has upright Forced Vial Capacity ( FVC ) 30 % 80 % predict normal value ERTexperienced subject ( nonambulatory ) : Has receive ERT alglucosidase alfa ( myozyme/lumizyme ) ≥2 year Is wheelchairbound ERTnaïve subject ( ambulatory ) : Must able walk 200500 meter 6MWT Has upright FVC must 30 % 80 % predict normal value Subject never receive alglucosidase alfa Subject receive treatment prohibit medication within 30 day Baseline Visit Subject , female , pregnant breastfeed screen Subject , whether male female , plan conceive child study Subject medical extenuate condition circumstance may , opinion investigator , pose undue safety risk subject compromise his/her ability comply protocol requirement Subject history allergy sensitivity miglustat iminosugars Subjects active systemic autoimmune disease lupus , scleroderma , rheumatoid arthritis . All subject autoimmune disease must discuss Amicus Medical Monitor Subjects active bronchial asthma . All subject bronchial asthma must discuss Amicus Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pompe , rhGAA</keyword>
</DOC>